@article {8121,
	title = {Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial},
	journal = {Annals of Oncology},
	volume = {11},
	year = {2000},
	note = {Cited By :65Export Date: 21 February 2017},
	month = {2000},
	pages = {799 - 805},
	abstract = {Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present prospective study was to evaluate the dose-response relationship of paclitaxel. Patients and methods: Since July 1996, 198 patients with non-operable NSCLC and measurable disease without previous chemotherapy entered the trial. Ninety nine patients (group A) were randomized to receive paclitaxel 175 mg/m2 in three-hour infusion plus carboplatin dosed to an area under the concentration-time curve of 6 every 3 weeks and 99 (group B) to receive the same regimen with paclitaxel increased to 225 mg/m2. Eligibility criteria included WHO performance status 0-2, documented inoperable stage IIIA and IIIB, IV, no brain metastasis, no prior chemotherapy and adequate renal and hepatic function. Patients in both groups were well-matched with baseline disease characteristics. Results: In group A with 90 evaluable patients, the response rate was 25.6\%(6 CR, 17 PR) whereas in group B with 88 evaluable patients, the response rate was 31.8\% (3 CR, 25 PR), P = 0.733. Median time to progression favored the high-dose paclitaxel (4.3 vs. 6.4 months, P = 0.044). The median survival was 9.5 months for group A versus 11.4 months for group B (P = 0.16). The one-year survival was 37\% for group A and 44\% for group B (P = 0.35). The best prognostic factor for one-year survival was the response rate (P \&lt; 0.0001). With a relative dose intensity of paclitaxel 0.94 in both groups, neurotoxicity (P = 0.025) and leucopenia (P = 0.038) were more pronounced in group B patients. No toxic death was observed. Conclusions: Higher dose paclitaxel prolongs the median time to progression but causes more neurotoxicity and leucopenia. The better response rate, the longer overall and better one-year survival seen with the higher dose of paclitaxel are not statistically significant.},
	keywords = {Dose response, NSCLC, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033811566\&doi=10.1023\%2fA\%3a1008389402580\&partnerID=40\&md5=72c3926dc1e0b73e25713eea4c61e4a0},
	author = {Kosmidis, P. and Mylonakis, N. and Skarlos, D. and Samantas, E. and Dimopoulos, M. and Papadimitriou, C. and Kalophonos, C. and N. Pavlidis and Nikolaidis, C. and Papaconstantinou, C. and Fountzilas, G.}
}
